Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued ...

Akili Interactive will release its video game treatment, EndeavorRx, for adults with ADHD, taking advantage of FDA flexibilities.

BOSTON—May 3, 2023 -- Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of ...

Akili noted in the results that EndeavorRx’s effects were largely consistent across both the 40% of participants who were also taking prescription medication for their ADHD and those who weren’t.

That slimdown was sparked by Akili’s plummeting stock price and the sizable gap between its revenues and operating expenses—which totaled $323,000 and $90.6 million, respectively, for all of 2022.

EndeavorOTC is Akili’s second digital ADHD therapeutic product to receive FDA authorization, and is the only FDA-authorized digital therapeutic for ADHD available without a prescription.

Akili’s marquee product is EndeavorRx, which they describe as a "first-of-its-kind attention treatment for children with ADHD, delivered through an action video game experience.” EndeavorRx is ...

Akili Inc AKLI announced the topline results of the STARS-ADHD-Adult trial evaluating EndeavorRx (AKL-T01) in adults with attention deficit/hyperactivity disorder (ADHD). The trial demonstrated ...

Akili, Inc., the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged ...

The Akili Employee Survey was conducted by Wakefield Research (www.wakefieldresearch.com) among 500 currently employed U.S. adults (49% female; 50% male; 1% non-binary) who have been diagnosed ...